Bicycle Therapeutics Ltd (BCYC) is a Healthcare · Biotechnology company listed on NASDAQ. Price $3.68 (+0.00%), Market cap $0.31B, 52-week low–high $4.31 ~ $8.87.
Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase II clinical trials for the treatment of high nectin-4 expressing tumors; nuzefatide pevedotin (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle tumor-targeted immune cell agonist molecule, which is in phase I/II targeting nectin-4 and agonizing CD137; and BT1702, a theranostic BRC molecule targeting MT1-MMP for
Financial statements, price targets, institutional (13F) holdings and related news for Bicycle Therapeutics Ltd are updated in real time on BlackAll Trade.
Bicycle Therapeutics Ltd trades at $3.68 (+0.00%). Real-time quotes and charts are available on BlackAll Trade.
Bicycle Therapeutics Ltd has a market cap of about $0.31B.
Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom.